scorecardresearchLupin Share Price Live NSE, BSE, Today - Lupin Stock Price

Lupin

BSE: 500257 | NSE: LUPIN | ISIN: INE326A01037 | SECTOR: Biotechnology & Drugs

889.05 8.25 (0.94%)

28 Jun 2023, 09:59 (IST)
  • Open

    881.00
  • High

    894.40
  • Low

    876.10
  • Prev Close

    880.80
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    404.59B
  • Volume

    31.98K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
  • Div.Yield

    -
  • Bid

    -
  • Ask

    889.35

Company Description

  • Biotechnology & Drugs
  • BSE

    500257
  • NSE

    LUPIN
  • ISIN

    INE326A01037

Lupin Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept. It diabetes brands include ONDERO and ONDERO MET.

Company Officers

  • Vinita Gupta

    Chief Executive Officer, Executive Director
  • Ramesh Swaminathan

    Executive Director, Global Chief Financial Officer, Chief Risk Officer, Head - Corporate Affairs
  • Rajendra Chunodkar

    President - Manufacturing Operations
  • Fabrice Egros

    President - Corporate Development and Growth Markets
  • Shahin Fesharaki

    President - Global Chief Scientific Officer
  • Spiro Gavaris

    President - U.S. Generics
  • Naresh Gupta

    President - API Plus and Global TB
  • Rajender Kamboj

    President - Novel Drug Discovery and Development
  • Cyrus Karkaria

    President - Biotechnology
  • Yashwant Mahadik

    President - Global Human Resources